Drug intelligence / Profile preview

evifacotrep

Development stage: Phase 2
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

Evifacotrep (BMS-986410) is a small molecule inhibitor of the transient receptor potential canonical 4 and 5 (TRPC4/5) ion channels. Developed by Bristol Myers Squibb, it is currently in Phase 1 clinical development for the treatment of mood and anxiety disorders, including major depressive disorder (MDD). TRPC4 and TRPC5 are non-selective cation channels expressed in brain regions associated with emotional processing, such as the amygdala and hippocampus. By inhibiting these channels, evifacotrep aims to modulate neuronal excitability and provide therapeutic benefit in psychiatric conditions where TRPC4/5 overactivity or signaling is implicated.

Other names: TRPC4/5 Inhibitor

Targets

TRPC5 (Transient receptor potential Canonical-5)TRPC4 (Transient receptor potential cation channel subfamily C member 4)

Beyond the preview

Go deeper on evifacotrep.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on evifacotrep.

Explore the full profile